http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109207575-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2017-07-02^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109207575-B |
| titleOfInvention | Gene marker and detection kit for predicting clinical effect of methotrexate on treating psoriasis |
| abstract | The invention belongs to the technical field of biology, and relates to a psoriasis medicament curative effect detection gene marker and a detection kit, and provides an LCE3D SNP locus rs41127 4112788AG genotype as a gene marker for predicting the clinical curative effect of methotrexate on treating psoriasis; a detection kit is provided by researching the relation between the genotype of the LCE3D SNP locus rs4112788 and the clinical curative effect of MTX on psoriasis treatment, the effective rate of MTX treatment intervention and the occurrence condition of the risk of hepatotoxicity for psoriasis patients carrying the genotype of the LCE3D SNP locus rs4112788AG are predicted and evaluated, the clinical curative effect of MTX on psoriasis treatment is facilitated to guide clinicians to formulate a proper MTX treatment intervention scheme, and a basis is provided for improving the clinical curative effect of MTX. |
| priorityDate | 2017-07-02^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 35 of 35.